Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
6.78
+0.21 (3.20%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Valneva SE Revenue
In the year 2024, Valneva SE had annual revenue of 169.58M EUR with 10.32% growth. Valneva SE had revenue of 52.94M in the quarter ending December 31, 2024, with 26.36% growth.
Revenue (ttm)
169.58M EUR
Revenue Growth
+10.32%
P/S Ratio
3.29
Revenue / Employee
237,837 EUR
Employees
713
Market Cap
577.05M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
VALN News
- 2 days ago - Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers - GlobeNewsWire
- 4 days ago - Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 6 days ago - Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine - Benzinga
- 6 days ago - Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country - GlobeNewsWire
- 11 days ago - Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2 - GlobeNewsWire
- 13 days ago - VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm - PRNewsWire
- 17 days ago - Valneva SE Shareholding Declaration - March 2025 - GlobeNewsWire
- 19 days ago - Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above - GlobeNewsWire